Lipoprotein(a) Reduction in Persons with Cardiovascular Disease | NEJM
Original Article from The New England Journal of Medicine — Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Original Article from The New England Journal of Medicine — Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
When AI tools recommend confirmatory diagnostic testing, patients may face new financial burdens if these recommendations are followed by their clinicians but not yet reflected…
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo-cont…
The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment…
A 26-year-old man presented with a 1-week history of fevers and bloody stools. A CT scan of the pelvis showed rectal thickening, and a flexible…
A 40-year-old man presented to the emergency department with a 5-day history of fevers, sore throat, fatigue, subjective weakness, and muscle and joint pains.
A 42-year-old woman presented with a 2-year history of a facial rash. A skin examination after removal of her makeup showed an indurated plaque, areas…
NEJM Group offers live web events covering the important topics impacting health care. See our upcoming schedule.